

Mumbai - 400 067 India

T +91 22 6606 1000 F +91 22 6606 1200 E legal.info@ajantapharma.com W www.ajantapharma.com



7<sup>th</sup> August 2023

	C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ	
Phiroze Jeejeebhoy Towers	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no.	

Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing **Regulations').** 

Pursuant to Regulation 39(3) of the SEBI LODR Regulations and in terms of SEBI Circular No. SEBI/HO/MIRSD/ MIRSD\_RTAMB/P/CIR/2022/8 dated 25th January, 2022, the Company has approved issuance of "Letter of Confirmation" on 4<sup>th</sup> August 2023 in lieu of share certificate(s), which were reported lost by the following shareholder:

Name of Shareholder	Folio No	Old Certificate No.	New Certificate No.	Distinctive Nos.	Shares
PARIDHI SHAH	000545	391 19424	19549	344626-345375 88087019-88087393	750 375

Kindly take the above information on record.

Thanking you,

Yours faithfully,

**Gaurang Shah** 

*VP* – *Legal & Company Secretary* 

